ClinVar Miner

Submissions for variant NM_033629.6(TREX1):c.416del (p.Ala139fs)

gnomAD frequency: 0.00004  dbSNP: rs763229085
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001045764 SCV001209635 pathogenic Aicardi-Goutieres syndrome 1; Chilblain lupus 1; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations 2023-12-30 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Ala139Valfs*21) in the TREX1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 176 amino acid(s) of the TREX1 protein. This variant is present in population databases (rs763229085, gnomAD 0.007%). This premature translational stop signal has been observed in individual(s) with clinical features of autosomal recessive Aicardi Goutieres syndrome and an unspecified abnormality of the nervous system or stroke (PMID: 19344873, 26633542, 31719132). ClinVar contains an entry for this variant (Variation ID: 843202). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects TREX1 function (PMID: 29387804). This variant disrupts the C-terminus of the TREX1 protein. Other variant(s) that disrupt this region (p.Arg164*, p.Trp210*) have been observed in individuals with TREX1-related conditions (PMID: 16845398, 26938784). This suggests that this may be a clinically significant region of the protein. For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV001567593 SCV001791308 pathogenic not provided 2023-06-20 criteria provided, single submitter clinical testing Published functional studies demonstrate a a significant decrease in enzymatic activity (McGlasson et al., 2017); Frameshift variant predicted to result in protein truncation, as the last 176 amino acids are replaced with 20 different amino acids, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (HGMD); This variant is associated with the following publications: (PMID: 26633542, 31719132, 26938784, 16845398, 29387804, 30219631, 27943079)
Institute of Neurology, Charite University of Medicine RCV002282434 SCV002571717 likely pathogenic Aicardi-Goutieres syndrome 1; Chilblain lupus 1; Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations; Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 2022-06-04 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.